You are here
Dr. Thomas Stinchcombe, Division of Medical Oncology, Duke UniversityAt the 2017 ASCO annual meeting, Dr. Thomas Stinchcombe, Division of Medical Oncology, Duke University, described how ablative therapy and reinitiation of erlotinib can be used in EGFR-mutant non-small cell lung cancer (NSCLC) with CNS or limited systemic disease progression. Prospective data presented by Jared Weiss, University of North Carolina, showed that this is associated with a progression-free survival of 5-6 months. He commented, “This is a viable strategy as we try and extend the life of each line of our therapies“.
How I optimize treatment for my patients with advanced squamous NSCLC: present options and future perspectives
LUIS PAZ-ARESLuis Paz-Ares reviews the current treatment strategies for squamous NSCLC and defines the differences between squamous and non-squamous NSCLC. He highlights the need for further research and better treatments, as even though small steps have been made in 1 st - and 2 nd -line, overall prognosis continues to be poor.
How I optimize treatment for my patients with advanced non-squamous NSCLC: present options and future perspectives
JOACHIM AERTSJoachim Aerts reviews the ESMO clinical practice guidelines for diagnosis, treatment and follow-up of metastatic non-squamous NSCLC which were updated in 2016. He reviews the treatment algorithm for 1 st -line and 2 nd -line, and comments on promising upcoming clinical trial data. He looks at the newest clinical trial data on targeted therapies, and refers to the need to sequence these therapies in order to give patients the best care possible. He comments on the future of therapy combinations for this patient population.
How I select the right treatment for the right patient: histological and molecular profiling challenges
FERNANDO LÓPEZ-RÍOSFernando López-Ríos is a pathologist who in this session addresses current issues in collecting quality samples to achieve the most accurate diagnoses, and describes the current state of analytical testing for NSCLC and the benefits and limitations of the many analytical tools. He then reviews how to present pathology findings in the way that best benefits clinicians and patients.
SILVIA NOVELLOSilvia Novello chairs this session on advanced NSCLC. The goal is to leave attendees better informed about: the reasons behind the limited treatment options, the advances towards better therapies and how to develop effective care plans using effective treatment sequencing and a multidisciplinary team.
Interview with Nicholas ThatcherWatch here what Nicholas Thatcher has to tell about the Satellite Symposium.
- In this video, Martin Reck, Head of the Oncology unit, LungenClinic Grosshansdorf, Germany, discusses the emergence of immunotherapy and the positive results of four randomized trials on immunotherapy vs. chemotherapy, showing benefit in overall survival. He also mentions that immunotherapy might work better than chemotherapy in selected patients and reviews treatment options for a specific population of patients with autoimmune diseases at baseline.
- Therapy of EGFR-mutated lung cancer was discussed in detail during the World Conference on Lung Cancer held in Vienna, including recent data. Federico Cappuzzo, Director Medical Oncology Department at Ospedale Civile, Livorno, Italy, provides insights into the management of EGFR-mutated NSCLC with the new molecule osimertinib and reviews the benefits and limitations of liquid biopsy.
- This session focuses on the overall landscape of ALK inhibitors for treatment of NSCLC. Enriqueta Felip, Head of the Medical Oncology Service of the Thoracic Tumors Committee, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the various ALK inhibitors currently available, including crizotinib, ceritinib and alectinib, as well as the possible treatment modalities with these drugs either as monotherapy or in combination. She also provides a brief overview of the various randomized trials which have shown positive results with these inhibitors and stresses the need for further trials in order to obtain more data in this area.
Advisory EditorImmunotherapy with nivolumab and pembrolizumab or a combination therapy have shown improvements in the survival of patients with squamous non-small-cell lung cancer. With many immunotherapeutic agents in the developmental phase, assigning patients to the best therapy will become ever more important and challenging.